Suchergebnisse - "Rolfo, Christian"

PubPharm (449)

1

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

enthalten in: Molecular cancer | 2024

von Puyalto, A. | Rodríguez-Remírez, M. | López, I. | +14

2

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

enthalten in: Molecular cancer | 2024

von Puyalto, A. | Rodríguez-Remírez, M. | López, I. | +14

3

Genomic ancestry and cancer among Latin Americans

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2024

von Ruíz-Patiño, A. | Rojas, L. | Zuluaga, J. | +8

4

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma : The ATOMIC-Meso Randomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Szlosarek, P. | Creelan, B. | Sarkodie, T. | +42

5

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Rolfo, C. | Madison, R. | Pasquina, L. | +6

6

The Chemoimmunotherapy Revolution in Resectable NSCLC-The Times They Are A-Changin'

enthalten in: JAMA oncology | 2024

von Rolfo, C. | Russo, A.

7

Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers

enthalten in: Cancer | 2024

von Rolfo, C. | Del Re, M. | Russo, A.

CommentOn: Cancer. 2024 Mar 15;130(6):913-926. - PMID 38055287

8

Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC

enthalten in: Journal of experimental & clinical cancer research : CR | 2024

von de Miguel-Perez, D. | Ak, M. | Mamindla, P. | +12

9

Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC

enthalten in: Journal of experimental & clinical cancer research | 2024

von de Miguel‑Perez, D. | Ak, M. | Mamindla, P. | +12

10

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors : a phase 2 randomized trial

enthalten in: Investigational new drugs | 2024

von Armstrong, A. | Geva, R. | Chung, H. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[45]